Filtered By:
Condition: Heart Failure
Drug: Diovan
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 48 results found since Jan 2013.
Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
ConclusionsStroke volume index is positively associated with complete titration of sacubitril/valsartan. Patients with low SVi are more prone to experience hypotension during titration
Source: ESC Heart Failure - March 23, 2022 Category: Cardiology Authors: Paolo Tolomeo,
Ottavio Zucchetti,
Emanuele D'Aniello,
Noemi Punzo,
Federico Marchini,
Luca Di Ienno,
Elisabetta Tonet,
Rita Pavasini,
Claudio Rapezzi,
Gianluca Campo,
Matteo Serenelli Tags: Short Communication Source Type: research
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
In conclusion, patients in BP strata ≥ 150/90 mmHg, but not patients in BP strata < 130/70 mmHg, were at increased risk for adverse outcomes in this hypertensive, high-risk population. Although benefit in preventing MI in relation to preventing stroke levels off for the lowest BPs, these data provide no support for a J-curve in the treatment of high-risk hypertensive patients . The increase in the ratio of MI to stroke with lower DBP indicates target organ heterogeneity in that the optimal on-treatment DBP for cerebroprotection is below that for cardioprotection.
PMID: 26511535 [PubMed - in process]
Source: Blood Pressure - February 14, 2016 Category: Hematology Tags: Blood Press Source Type: research
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial
Conclusions
In the high CV risk, hypertensives of the VALUE trial reducing BP consistently to <140/90 mmHg had marked beneficial effects both when data were calculated as proportion of visits at BP target or as on-treatment mean BP. Reducing BP to <130/80 mmHg led only to some possible further benefit on stroke, whereas the risk of other outcomes remained substantially similar to or slightly greater than that seen at the higher target. Thus, aggressive BP reductions when CV risk is high may not offer substantial advantages, except perhaps in patients or conditions in which stroke risk is particularly common.
Source: European Heart Journal - March 21, 2016 Category: Cardiology Authors: Mancia, G., Kjeldsen, S. E., Zappe, D. H., Holzhauer, B., Hua, T. A., Zanchetti, A., Julius, S., Weber, M. A. Tags: Hypertension Source Type: research
Effects of Valsartan Versus Amlodipine in Diabetic Hypertensive Patients With or Without Previous Cardiovascular Disease
In conclusion, the ARB- and the CCB-based treatments exerted similar protective effects of CVD events regardless of the presence of previous CVD. For stroke events, the ARB may have more protective effects than the CCB in diabetic hypertensive patients with previous CVD.
Source: The American Journal of Cardiology - September 16, 2013 Category: Cardiology Authors: Kentaro Yamashita, Takahisa Kondo, Takashi Muramatsu, Kunihiro Matsushita, Takanori Nagahiro, Kengo Maeda, Satoshi Shintani, Toyoaki Murohara Tags: Systemic Hypertension Source Type: research
Effects of Blood Pressure Lowering Agents on Cardiovascular Outcomes in Weight Excess Patients: A Systematic Review and Meta-analysis
ConclusionsIn hypertensive subjects with excess weight, diuretics are more effective for preventing HF and stroke than CCB and ACEI, respectively. CCB are a good first-line choice for prevention of cardiovascular disease, except HF.
Source: American Journal of Cardiovascular Drugs - January 2, 2020 Category: Cardiology Source Type: research
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
We examined each outcome individually in secondary analyses, in addition to all-cause mortality. RESULTS:We identified 54 186 patients with diabetes who started taking an angiotensinreceptor blocker during the study period. After multivariable adjustment, patients who took either telmisartan (adjusted hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.74-0.97) or valsartan (adjusted HR 0.86, 95% CI 0.77-0.95) had a lower risk of the composite outcome compared with patients who took irbesartan. In contrast, no significant difference in risk was seen between other angiotensin-receptor blockers and irbesartan. In secondar...
Source: cmaj - July 8, 2013 Category: Journals (General) Authors: Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM Tags: CMAJ Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | DOI:10.3346/jkms.2023.38.e202
Source: Journal of Korean Medical Science - June 27, 2023 Category: Biomedical Science Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
